👀Ryan Lu's Gene Therapy for Vision Loss Enters Human Trials
A gene therapy for age-related blindness is about to hit human trials
TL;DR
Ryan Lu's gene therapy, ER-100, which aims to reverse age-related vision loss, is now in human trials. The therapy, tested in mice, could offer hope for those with macular degeneration and glaucoma.
Ryan Lu, a 34-year-old researcher, has developed a gene therapy called ER-100 that aims to reverse age-related vision loss. The therapy, which involves reprogramming cells to a youthful state, has shown promise in mice, with optic nerves regenerating and vision improving. Now, it's entering human clinical trials, focusing on glaucoma patients. This breakthrough could be a game-changer for millions suffering from age-related blindness. The treatment, however, remains toxic to many cell types, highlighting the need for further research. Lu's work, published in Nature in 2020, has sparked significant investment in anti-aging medicine.
Key Points
Ryan Lu's gene therapy, ER-100, aims to reverse age-related vision loss in humans, entering clinical trials this year.
Lu's research, published in Nature in 2020, showed optic nerves regenerating in mice, offering hope for those with macular degeneration.
The therapy involves injecting cells with a gene therapy to restore nerves to a youthful state, a process called reprogramming.
The treatment, ER-100, is now in human trials for glaucoma patients, marking a significant step in anti-aging medicine.
Lu's work has sparked investment in anti-aging medicine, with US tech billionaires placing huge bets on private companies.
Why It Matters
If you're a researcher in anti-aging medicine, Ryan Lu's work on gene therapy for vision loss is a must-watch. The ER-100 treatment, now in human trials, could offer hope for millions suffering from age-related blindness. However, the treatment remains toxic to many cell types, highlighting the ongoing need for research and development.
Frequently Asked Questions
Why does this matter?
If you're a researcher in anti-aging medicine, Ryan Lu's work on gene therapy for vision loss is a must-watch. The ER-100 treatment, now in human trials, could offer hope for millions suffering from age-related blindness. However, the treatment remains toxic to many cell types, highlighting the ongoing need for research and development.
What happened?
Ryan Lu's gene therapy, ER-100, which aims to reverse age-related vision loss, is now in human trials. The therapy, tested in mice, could offer hope for those with macular degeneration and glaucoma.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.
Join 3,464 builders reading daily.